欢迎辞

欢迎您出席由博鳌亚洲论坛主办，中国医药工业科研开发促进会（以下称中国药促会）协办的“医药行业 CEO 圆桌会议”。

生物医药产业已成为战略性新兴产业，它的创新发展已成为全球经济活动中的重要议题。结合博鳌亚洲论坛 2014 年年会的主题“亚洲新未来：寻找和释放新的发展动力”，为更好地促进中国医药行业的创新、产业化、国际化，借助博鳌亚洲论坛 2014 年年会这样一个平台，中国药促会组织召开“医药行业 CEO 圆桌会议”，旨在搭建一个政府要员、工商界和学术界领袖对话的高层次平台，探讨中国与亚洲乃至世界医药产业创新发展的相关话题，最终为中国医药产业和健康事业的发展服务并创建一个良好的生态环境。

本次会议主题为“商业伦理与市场环境”，您将与参会代表围绕医药产业的社会责任和创新发展主题，特别是如何完善行业生态环境，提高人民群众的健康保障水平等内容进行深入研讨和交流。

再次感谢您对本次会议的大力支持！

宋瑞霖

中国医药工业科研开发促进会

2014 年 4 月 9 日

Boao Forum for Asia Annual Conference 2014
CEO Roundtable of Pharmaceutical Industry
April 9th, 2014

Welcome to the “CEO Roundtable of Pharmaceutical Industry” hosted by Boao Forum for Asia (BFA) and co-organized by China Pharmaceutical Industry Research and Development Association (SINO-PhIRDA).

Now the pharmaceutical industry is regarded as one of the strategic emerging industries around the world, thus its innovative development has become the significant topic during international economic process. In order to promote innovation, industrialization and internationalization of pharmaceutical industry in China, SINO-PhIRDA helps BFA organize a CEO Roundtable of Pharmaceutical Industry, making efforts to establish a platform for government officials, scholars in academia and senior managers in industry to discuss related topics on innovative development in pharmaceutical industry in China, Asia or even the whole world.

The theme of this roundtable is Ethics amid Market Complexities. During the roundtable, you will have a discussion with the participants on topics of social responsibility and innovative development of pharmaceutical industry, especially those on how to improve eco-system and construct a mature and responsible pharmaceutical market so as to improve public healthcare system.

Thanks for your great support to our roundtable.

Cordially,
SINO-PhIRDA

Song Ruilin

Agenda

CEO Roundtable of Pharmaceutical Industry, Ethics amid Market Complexities
Time: 16:30-18:30, April 9th
Place: ICC, Level I, Peacock 1
Host: Mr.Song Ruilin, Executive President of SINO-PhIRDA

Session 1: Opening (16:30-16:35)

16:30-16:35 Introduction of the guests, background and form of the Roundtable by the host

Session 2: Table Discussion (16:35-17:20)

In this session, the delegates will be divided into three groups on three tables to discuss on three topics.
Topic of Table 1:
For the pharmaceutical enterprises and pharmaceutical industry, how to fulfill their social responsibilities complying with the laws, regulations and business ethics requirements?
Topic of Table 2:
For the government authorities, how to establish a policy environment to encourage innovative development of pharmaceutical industry?
Topic 3 of Table 3:
In order to make an open, transparent and efficient market environment, how to set up a platform with dialogue and communication mechanism between pharmaceutical companies/pharmaceutical industry and government?
Before the discussion, each table elects a representative to make a keynote address on respective topic for 5 minutes each.

16:35-16:40 Representative of Table 1:Xijun Yan
Chairman of the Board, Tasly Holding Group
16:40-16:45 Representative of Table 2:Olivier Charmeil
President& CEO of Sanofi Pasteur
16:45-16:50 Representative of Table 3:Alok Kanti
President of Bayer Pharma Greater China
16:50-17:20 Discussion(On Each topic and Boao Consensus of Pharmaceutical industry)

Session 3: (17:20-18:05)

In this session, all the delegates will discuss together, and each table elects one representative to make a summarizing remark for their own table.

17:20-17:25 Representative of Table 1:James Li
Amgen VP, Greater China General Manager
17:25-17:30 Representative of Table 2:Qiyu Chen
Chairman of the Board, Shanghai Fosun Pharmaceutical Group Co., Ltd
17:30-17:35 Representative of Table 3: Piaoyang Sun
Chairman of the Board, Jiangsu Hengrui Medicine Co., Ltd
17:35-18:05 Q&A (Propose different ideas and make discussion)

Session 4: (18:05-18:30)

In this session, the delegates will sign Boao Consensus of Pharmaceutical industry, and the government official will give a speech.

18:05-18:15 Summarize the conference by the host and delegates sign the Boao Consensus of Pharmaceutical industry
18:15-18:30 Concerned government official makes speeches and Q&A

会议议程

时间：4 月 9 日 16:30–18:30

地点：海南博鳌 国际会议中心一层孔雀 1 厅

主持人：中国医药工业科研开发促进会执行会长宋瑞霖

1、会议开幕（16:30–16:35）

16:30–16:35 主持人介绍会议来宾 、背景及会议形式

2、分桌讨论（16:35–17:20）

嘉宾分为三桌展开讨论：

第一桌议题：医药企业和医药产业界如何按照法律法规和商业道德规范的要求，履行社会责任；

第二桌议题：政府如何建立起鼓励医药产业创新发展的政策环境；

第三桌议题：医药行业、医药企业与政府部门如何建立对话交流的平台与机制，营造一个公开透明高效的市场环境。

展开讨论之前，每桌派一位代表作主旨发言。

16:35–16:40 第一桌代表：天士力控股集团董事局主席闫希军

16:40–16:45 第二桌代表：赛诺菲巴斯德全球 CEO Olivier Charmeil

16:45–16:50 第三桌代表：拜耳医药中国区总裁 Alok Kanti

16:50–17:20 自由讨论（结合本桌主题和“博鳌医药产业界共识讨论）

3、共同讨论（17:20–18:05）

所有参会嘉宾共同讨论，三桌讨论嘉宾分别对本桌讨论的议题分别进行总结性发言。

17:20–17:25 第一桌代表：安进副总裁，大中华区总经理李怡平发言

17:25–17:30 第二桌代表：上海复星医药股份有限公司董事长陈启宇

17:30–17:35 第三桌代表：江苏恒瑞医药股份有限公司董事长孙飘扬

17:35–18:05 嘉宾互动（提出不同意见，展开讨论）

4. 签署共识，领导讲话（18:05–18:30）

18:05–18:15 主持人总结，嘉宾签署博鳌医药产业界共识

18:15–18:30 参会领导讲话并与嘉宾互动

The participants
参与单位与嘉宾简介

(Names are listed in the order of presence)
(按照出场顺序排列)

Brief Introduction of SINO-PhIRDA

中 国 药 促 会

Founded in 1988, China Pharmaceutical Industry Research and Development Association (SINO-PhIRDA) is registered as a non-profit organization by the Ministry of Civil Affair of China at the first national level.

At current stage, SINO-PhIRDA has more than 60 members, which are mainly of three major categories: First, national pharmaceutical enterprises excelling at medical innovation; Second, universities, colleges and research institutions conducting pharmaceutical research and development; Third, clinical institutions featuring high skills in applicable research on new drugs, especially those undertake "major new drug innovation" technological platform for good clinical practice. SINO-PhIRDA will exert great effort to grow into a social organization featuring "university industry collaboration", an organization which centers on research and development, persists in innovation to achieve unmet clinical requirements.

Major work of SINO-PhIRDA includes: First, to promote communication and innovative development of our member units and even the whole pharmaceutical industry through forums, press conferences, summits, etc; Second, to make efforts to establish an international exchange platform for our member units through cooperation with foreign embassies and foreign associations such as PhRMA to stimulate communication between China and foreign countries in pharmaceutical field; Third, to improve the website of SINO-PhIRDA and provide collecting, arranging, revising and consulting service of pharmaceutical information, which includes the following internal e-magazines such as the bimonthly journal Scientific and Technological Development Information on Pharmacy, Daily Pharmaceutical Information Brief, Weekly International Pharmaceutical Development Tendency and Research Information Brief; Fourth, to conduct pharmaceutical policy research, propose valuable suggestions on healthcare reform and the development of pharmaceutical industry , with the help from the National Health and Family Planning Commission, Ministry of Commerce, Ministry of Industry and Information Technology, CFDA and other concerned government departments.

Focusing on the principle of "Innovation, Industrialization, Internationalization", SINO-PhIRDA will strengthen self-discipline, promote technological progress for and enhance healthy development of our national pharmaceutical industry, making constant contributions to the greater economic development of our country and public health.

中国医药工业科研开发促进会（简称中国药促会，英文名称为 China Pharmaceutical Industry Research and Development Association，英文缩写为 SINO-PhIRDA）成立于 1988 年，是经国家民政部登记注册的非营利性全国性一级社会团体组织。

目前，中国药促会有会长及会员单位 60 多家，主要由三方面的成员构成：一是，在医药创新方面具有代表性的民族医药企业；二是，从事医药研发的高等院校和科研院所；三是，在新药临床研究领域具有较高水平、特别是承担“重大新药创制”科技重大专项新药临床评价研究（GCP）技术平台的临床医疗机构。中国药促会将努力建设成为以研发为核心，以创新为宗旨，以临床需求为导向，“产学研用”紧密结合的促进医药科研开发的社会团体。

中国药促会的工作内容主要包括：一是，通过举办各种论坛、发布会、大型会议等促进会员单位乃至整个医药产业互相交流、创新发展；二是，通过与美国药品研发和制造商协会（PhRMA）等国外协会和外国驻华使馆合作，共同寻求推动中外医药产业领域的合作交流，为会员单位搭建国际交流平台；三是，为会员单位提供医药信息搜集、整理、评价、咨询的服务，包括编辑双月刊刊物《医药科研开发信息》和每日《医药信息简报》、每周《国际医药产业发展动态与研发信息简报》、《行业热点评析》等内部电子刊物以及建设药促会官方网站等内容；四是，开展医药政策研究工作，在卫生部、商务部、工信部、国家食品药品监督管理局等有关政府部门和医药科研学术机构和企业的支持下，为医改事业和医药产业发展建言献策。

中国药促会将围绕“创新、产业化、国际化”的宗旨，加强行业自律，推动我国医药行业的技术进步，促进我国医药产业健康发展，为加快我国经济社会发展、保障人民群众健康不断做出贡献！

Song Ruilin

Executive President
China Pharmaceutical Industry Research and Development Association

宋瑞霖

执行会长
中国医药工业科研开发促进会

Mr. Song Ruilin, L.L.B. from China University of Political Science and Law, EMBA from China Europe International Business School, is the Executive President of China Pharmaceutical Industry Research and Development Association (SINO-PhIRDA); Executive Director-General of Research Center for Medicinal Policy of Chinese Pharmaceutical Association; Executive Deputy Director of the Research Center of National Drug Policy & Ecosystem, China Pharmaceutical University.

Before 2008, Mr. Song was mainly engaged in the legislative review and research of health and medicine and was former Deputy Director-General of the Department of Education, Science, Culture and Public Health in Legislative Affairs Office at State Council of China. He participated in China's health legislation activities from 1987 to 2006, in charging of the inspection and review of current Law of Pharmaceutical Administration, Law of Food Safety, Law of the Prevention and Treatment of Infectious Diseases, etc., which enabled him to become an expert on Chinese healthcare legislation and law. In early 2006, Mr. Song performed research on healthcare reform asa visiting scholar at Sydney University in Australia. After returning to China in 2008, Mr. Songparticipated in the establishment of Research Center for Medicinal Policy at Chinese Pharmaceutical Association, which then became a think-tank on medical policy, innovative medicines, essential drugs and pharmacoeconomics of the country. Also in the same year, he participated in the research activities of Health China 2020 Strategic Project organized by the Ministry of Health and was appointed as the Deputy-Director of experts group of national medicinepolicy subproject. Since November 2009, Mr. Song was elected as the Executive President of SINO-PhIRDA.

Currently, Mr. Song also undertakes several social positions, such as Standing Director of Chinese Pharmaceutical Association (CPA), Arbitrator of China International Economic and Trade Arbitration Commission (CIETAC), Standing Director of China Chamber of International Commerce (CCOIC), Vice Chairman of Biopharmaceutical Committee under CCOIC and Adjunct Professor of China Europe International Business School and Shenyang Pharmaceutical University.

宋瑞霖，毕业于中国政法大学，取得法学学士学位；中欧国际工商学院取得工商管理硕士。现任中国医药工业科研开发促进会执行会长；中国药学会医药政策研究中心执行主任；中国药科大学国家药物政策与医药产业经济研究中心执行副主任。

在 2008 年之前，宋瑞霖先生主要从事卫生医药方面的立法审查和研究工作，曾任国务院法制办公室科教文卫法制司副司长。他参与了 1987 年至 2006 年期间中国卫生立法方面的所有活动，其中包括《中华人民共和国药品管理法》、《中华人民共和国食品安全法》和《中华人民共和国传染病防治法》等，使之成为中国卫生医药法律专家。2006 年初，宋先生赴澳大利亚悉尼大学作为访问学者研究医药卫生体制改革。2008 年他由海外返回中国，参与建立中国药学会医药政策研究中心的工作。该中心是研究国家重大医药政策、创新药物、基本药物和药物经济学的智库。同年担任卫生部“健康中国 2020 战略规划”药物政策研究专家组副组长。自 2009 年 11 月起，当选为中国医药工业科研开发促进会执行会长。

现担任的社会职务：中国药学会常务理事、中国国际经济贸易仲裁委员会仲裁员、中国国际商会常务理事及生物医药委员会副主席、中欧国际工商学院和沈阳药科大学兼职教授。

TASLY HOLDING GROUP
天士力控股集团

Tasly Holding Group

天 士 力 控 股 集 团

Tasly Holding Group was founded in 1994, which has become a globalized hi-tech enterprise by taking Great Health industry as the guideline, pharmaceutical industry as the core, healthcare industry as well as medical rehabilitation, health maintenance, healthcare management & services as the two wings. The company is dedicated to build the No.1 brand for modernized Chinese medicine, to be the leading brand and to promote the continuous and fast development of the Great Health industry by adhering to the business philosophy of "To Pursue Harmonization of Man and the Nature, To Improve the Quality of Life".

Tasly Group is actively advocating, propelling and executing the establishment of the five systems, which are to establish Concept System, to promote Educational System, to innovate Technological System, to develop Industrial System and to perfect Service System of the Great Health industry. By implanting the "Five-one Project", Tasly Group has been focusing on well production of one pack of drug, one bottle of water, one cup of tea, one bottle of wine and one set of healthcare management plan, with a vision to realize people's desire of achieving "Optimized Birth, Prolonged Life, Delayed Illness and Unruffled Death ".

With technology innovation as the foundation, pharmaceutical industry of Tasly Group has successfully established a cluster of products represented by Compound Danshen Dripping Pill, Diqing® and Pro-UK®, in which, Compound Danshen Dripping Pill successfully completed United States FDA Phase 2 trials in 2010, and global Phase 3 trials are currently undergoing.

With the support of the technology advantage, Tasly Group has gradually expanded the Great Health industry by establishing a series of industrial systems covering the fields of Biological Puer Tea(branded Deepure®), healthy drinking water, healthcare products, functional foods, manufacturing & distributing of modernized white wine (branded Guotai®) as well as medical rehabilitation, health maintenance and healthcare management & services industry.

天士力控股集团创建于 1994 年，是以大健康产业为主线，以生物医药产业为核心，健康保健产业和医疗康复、健康养生、健康管理与服务业为两翼的高科技国际化企业集团。集团秉承“追求天人合一，提高生命质量”的企业理念，打造现代中药第一品牌，大健康产业领先品牌，推进大健康产业持续快速发展。

天士力集团积极倡导、推动和实践大健康五大体系建设，即：树立大健康理念、普及大健康教育、创新大健康技术、发展大健康产业、完善大健康服务，围绕让人们“生得优、活得长、病得晚、走得安”的人生期望目标，全力打造做好一盒药、一瓶水、一杯茶、一樽酒、规划设计一套健康管理方案的“五个一”工程。努力成为大健康产品的创造者、大健康管理方案的设计者、大健康文化的践行者。

集团生物医药产业立足科技创新，开发培育了复方丹参滴丸、帝清、普佑克为代表的医药产品集群。复方丹参滴丸 2010 年顺利通过 FDA Ⅱ期临床试验，目前在全球开展Ⅲ期临床试验。

借助生物医药领域技术优势，集团逐渐扩展大健康产业，形成了以“帝泊洱”为品牌的生物普洱茶、健康饮用水以及保健品、功能食品产业体系、以“国台”为品牌的现代白酒产供销体系、以湖南湘雅博爱康复医院等为启航的医疗康复、健康养生、健康管理与服务产业。

Yan Xijun

Chairman of the Board
Tasly Holding Group.

闫希军

董事局主席
天士力控股集团

TASLY HOLDING GROUP
天士力控股集团

Yan Xijun, Ph.D., Chief Pharmacist. Founder and Chairman of the Board of Tasly Holding Group. Representative of the 11th and the 12th National People's Congress. Dr. Yan's social alliances include President of China Pharmaceutical Industry Research and Development Association, Vice Chairman of the Working Committee on Popular Science of Chinese Pharmaceutical Association, Member of the Chinese Pharmaceutical Association Advisory Committee on Study of National Pharmaceutical Industry Policy, Member of the Committee on Techniques and Experts for the Standardization of the Traditional Chinese Medicine, Chairman of the World Chinese Medicine Alliance.

Dr. Yan has been dedicating to new drug R&D and pharmacy administration as well as research and practice of modernization and globalization of Chinese medicine. Taking component Chinese medicine as the leading factor, he has pioneered a new model for R&D and industrialization of modernized Chinese medicine, and led Tasly Group become a leading company in modernized Chinese medicine development. At present, Dr. Yan further made a systemic proposal of the Great Health development strategy. By focusing on the five Great Health systems of philosophy, education, technology, industry and service, and by closely holding on to the three links of Preventive Treatment, Disease Treatment and Later-stage Treatment, to actively develop A Bottle of Water, A Cup of Tea, A Bottle of Wine and A Set of Healthcare Management Program on the basis of the well-made of A Box of Medicine. With such development strategy, Dr. Yan has positioned Tasly group as a hi-tech and international enterprise group which take pharmaceutical industry as the core, healthcare & medical rehabilitation as well as health regimen management & service as the two wings.

Honors and awards received by Dr. Yan include Third Prize of National Science and Technology Progress Award, First Prize of Tianjin Science and Technology Progress Award, First Prize of National Enterprise Management Innovation Achievement, National Labor Models, National Outstanding Scientist, National Outstanding Pharmaceutical Entrepreneur, National Outstanding Individual of Healthcare Company and National Top Ten Innovative Leaders. Military honors and awards include one Second-class and four Third-class Military Merit citations, Second Prize of the Military Science and Technology Progress Award, and National Military Outstanding Entrepreneur.

闫希军，博士，主任药师，国务院特殊津贴专家。天士力控股集团创始人，董事局主席。第十一届、十二届全国人大代表。并任中国医药工业科研开发促进会年度会长、中国药学会科普工作委员会副主任委员、中国药学会“国家医药产业政策研究”项目专家指导委员会委员、中医药标准化专家技术委员会委员、中医药世界联盟董事局主席等职务。

闫希军先生长期致力于药剂研发和药事管理，以及中药现代化和国际化的研究与实践，开创了以组分中药为主导的现代中药新药开发与产业化新模式，带领天士力控股集团发展成为现代中药的领军企业。现在，闫希军先生又系统地提出了大健康的发展思路，围绕大健康理念、教育、技术、产业、服务五大体系，紧紧抓住“治未病、治已病、治未病”三个环节，在做好“一盒药”的基础上，努力开发“一瓶水”、“一杯茶”、“一樽酒”、“一套健康管理方案”，从而引领天士力控股集团走向以生物医药产业为核心，以健康保健产业和医疗康复、健康养生管理与服务产业为两翼的高科技国际化企业集团。

曾获国家科技进步三等奖、天津市科技进步一等奖和国家级企业管理创新成果一等奖，获“全国劳动模范”、“全国优秀科技工作者”、“全国优秀社会主义事业建设者”、“全国医药杰出企业家”、“全国卫生产业企业先进个人”、“中国十大创新人物”等荣誉。并荣立军队二等功一次、军队三等功四次，获军队科技进步二等奖两项，获“全军优秀企业家”称号。

赛诺菲

Sanofi Group

赛诺菲集团

Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi globally have more than 110,000 employees, and present in 100 countries. In 2013, Sanofi's net sales amounted to €32,951 million. Sanofi is listed in Paris and New York respectively.

Sanofi Pasteur, the vaccines division of Sanofi, is a worldwide leader of vaccines. With innovative vaccines preventing influenza, pediatric infectious diseases, and pneumococcal disease, Sanofi Pasteur contributes to the advancement of disease prevention in China.

赛诺菲是一家全球领先的多元化医药健康企业，专注于患者需求，研究、开发并推广创新的治疗方案。赛诺菲在七大增长平台拥有核心优势：糖尿病综合管理、人用疫苗、创新药物、健康药业、新兴市场、罕见病（健赞）和动物保健。目前，赛诺菲拥有 11 万余名员工、遍及 100 多个国家。2013 年，赛诺菲净销售额达 329.51 亿欧元。赛诺菲分别在巴黎（欧洲证交所代号：SAN）和纽约（纽约证交所代号：SNY）上市。

赛诺菲巴斯德是集团疫苗事业部，作为全球最大的专业致力于人用疫苗研发和生产企业，每年生产超过 10 亿剂疫苗，可预防 20 种疾病，使全球超过 5 亿人获得免疫保护。

Olivier Charmeil

President & CEO
Sanofi Pasteur

夏立维

总裁兼首席执行官
赛诺菲巴斯德

赛诺菲

Mr. Oliver Charmeil was appointed CEO of Sanofi Pasteur, the Vaccines Division of Sanofi, in January 2011.Olivier, previously Senior Vice President Global Operations Asia/Pacific and Japan, reports directly to Christopher A. Viehbacher, Chief Executive Officer, Sanofi, and is a member of the Sanofi Executive Committee.

He began his career in the Mergers & Acquisitions department of Bank of the European Union, from 1989 to 1994.

Olivier joined Sanofi Pharma in 1994 as head of Business Development. Subsequently, he held various posts within the Group, including Chief Financial Officer (Asia) for Sanofi-Synthélabo in 1999 and Attaché to the Chairman, Jean-François Dehecq in 2000, before being appointed as Vice President, Development within the Sanofi-Synthélabo International Operations Directorate, where he was responsible for China and support functions.

In 2003, Mr. Oliver Charmeil was appointed CEO of Sanofi-Synthélabo France, before taking the position of Senior Vice President, Business Management & Support within the Pharmaceutical Operations Directorate. In this role, he piloted the operational integration of Sanofi-Synthélabo and Aventis. He was appointed to Senior Vice President, Asia/Pacific & Japan, Pharmaceutical Operations, in February 2006.

Mr. Oliver Charmeil is a graduate of HEC (Ecole des Hautes Etudes Commerciales) and of the Institut d'Etudes Politiques in Paris.

Olivier Charmeil（夏立维）于 2011 年 1 月开始出任赛诺菲下属疫苗事业部赛诺菲巴斯德总裁兼首席执行官。在此之前，夏立维担任全球制药运营部（分管亚太区和日本）高级副总裁，向集团首席执行官 Christopher A. Viehbacher 魏巴赫先生汇报，是集团执行委员会委员。

1989 至 1994 年，夏立维在欧盟银行的收购兼并部门任职，他的职业生涯由此开始。

1994 年，夏立维加入赛诺菲制药，负责业务拓展。随后，他曾在集团历任多个重要职务，其中包括赛诺菲－圣德拉堡制药集团亚洲首席财政官（1999 年）和董事长 Jean-François Dehecq 的业务助理（2000 年），此后任赛诺菲－圣德拉堡国际运营副总裁，负责中国和支持部门的工作。

2003 年，夏立维担任赛诺菲－圣德拉堡法国分公司董事长兼首席执行官，随后又任制药运营部业务管理和支持高级副总裁，负责赛诺菲－圣德拉堡与安万特的运营合并。2006 年 2 月，夏立维就任集团制药运营亚太区和日本高级副总裁，并自 2008 年 1 月 1 日起负责日本的运营。

夏立维生于 1963 年，毕业于法国高等商业研究学院（HEC，Ecole des Hautes Etudes Commerciales）和巴黎政治学院（Institut d'Etudes Politiques）。

Bayer HealthCare

拜耳医药保健有限公司

Bayer HealthCare is one of the world's leading, innovative companies in the healthcare and medical industry and is based in Leverkusen, Germany, with more than 55,300 employees worldwide. Bayer HealthCare is committed to research, develop, manufacture and market innovative products that improve human and animal health worldwide. The products enhance well-being and quality of life by diagnosing, preventing and treating disease.

The relationship between Bayer HealthCare and China dates back to the early 20th century. In 1936, Bayer established its first production company in China, which manufactured a series of products including the world famous pain killer Aspirin. At present, Bayer HealthCare has 6,000 employees in China and is headquartered in Beijing with facilities in Beijing, Guangzhou, Chengdu and Qidong, Jiangsu.

The major business units of the company include Bayer Pharmaceuticals, Consumer Care and Animal Health. With presence in more than 100 cities, the product line of Bayer Pharmaceuticals covers general medicine, women's health, specialty medicine and diagnostic imaging.

As a responsible corporate citizen, Bayer HealthCare is fully dedicated to fulfill its commitments to benefit the community, the people and the society. Bayer HealthCare closely cooperates with local authorities and NGOs to launch key CSR initiatives including "Go West" Project, "Go Rural" Project, "Health Education Tour for the Enterprises' Employees in Central and Western Region" Project, China Community Health Promotion (CCHP) Program, the "Health Cabin" and "Bayer Health Promotion Cup" Community Competition to support and promote the development of public health in China.

拜耳医药保健是拜耳集团的子集团，总部位于德国勒沃库森，是一家在世界医药保健领域内居领先地位的创新型医药公司，在全球拥有超过 55,300 名员工。拜耳医药保健致力于研发、生产和销售能够改善人类和动物健康的创新产品。这些产品通过对疾病的诊断、预防和治疗，提高了人们的整体健康水平和生活质量。

拜耳医药保健与中国的渊源可以追溯到 20 世纪初。1936 年，拜耳在中国建立了第一个生产公司，生产一系列的产品，其中包括世界著名的阿司匹林止痛药。目前，拜耳医药保健在中国拥有 7，000 名员工，总部设在北京，并在北京、广州、成都和江苏启东建有生产基地。

公司的业务部门包括拜耳医药保健处方药、保健消费品和动物保健。拜耳医药保健处方药业务遍及 330 多个城市，开发、生产和销售心血管疾病、感染、内分泌、泌尿系统、肿瘤、妇科等领域多种高科技专利药品。

作为一家负责任的企业公民，拜耳医药保健全面致力于履行其造福社区、民众和社会的承诺。拜耳医药保健与政府和公益组织密切合作，启动了许多重要的企业社会责任项目，包括“走进西部”项目，“走进基层”项目，“中国企业员工健康行 · 健康领跑中西部”活动，中国社区健康促进项目，“拜耳健康小屋”和“拜耳健康促进杯”社区竞赛等，以支持和促进中国公共卫生事业的发展。

Alok Kanti

President of Bayer Pharma China
PMT Member, Bayer Pharma AG

康洛克

中国总裁，全球管委会成员
拜耳医药保健

Mr.Alok Kanti was appointed as President, Bayer Pharma Greater China, effective July 1, 2012, based in Beijing, China.

Prior to this position, Mr.Alok Kanti commenced his role as the Regional Head for Bayer HealthCare Pharmaceuticals Asia Pacific since January 1, 2010, based in its regional headquarters in Singapore.

In a span of 18 years, Mr.Kanti has risen up the ranks and been appointed several key positions within the Bayer organization. Prior to the role, Mr.Kanti was based in Berlin, Germany as the Head of Commercial Operations, at Intendis GmbH, a subsidiary of Bayer HealthCare specializing in dermatologicals since May 2007.

Mr.Kanti has spent seven years in Asia Pacific since July 2000: the first two years in the Philippines as Country Division Head for Bayer Philippines and the following five years in Singapore as the Head of Bayer HealthCare, South East Asia & Pakistan sub-region.

Mr.Kanti started his professional career with Bayer in June 1994 as an International Management Trainee with Bayer Inc. in Canada. Three years later, he took on the position of Assistant to Region Head, Regions of the World (ROW), within the Pharmaceutical division of Bayer AG, headquartered in Leverkusen, Germany. He then spent the next two years working on International Strategic Marketing based in Wuppertal, Germany.

Mr.Kanti obtained his Bachelors degree in Civil Engineering from University of Delhi in 1989 and his Masters degree in Business Management from the Asian Institute of Management in 1994.

康洛克先生自 2012 年 7 月 1 日起担任拜耳医药保健大中华区总裁，办公地点位于北京。

此前，康洛克先生曾于 2010 年 1 月 1 日起担任拜耳医药保健处方药亚太区总裁，工作地点位于新加坡的区域总部。

在这之前的 18 年时间里，康洛克先生逐步获得提升，在拜耳担任过多个重要职位。在担任亚太区负责人之前，他在德国柏林的 Intendis 公司负责商务运营。2007 年 5 月起，Intendis 开始成为拜耳医药保健的一家子公司，其专业领域是皮肤病学。

自 2000 年 7 月开始，康洛克先生在亚太区工作了七年。最初的两年中，他担任拜耳菲律宾总经理。之后，他在新加坡工作了五年，担任拜耳医药保健东南亚及巴基斯坦区域负责人。

1994 年 6 月，作为一名国际管理专业的实习生，康洛克先生在拜耳加拿大公司开始了他的职业生涯。三年后，他在拜耳（集团总部位于德国勒沃库森）处方药部门工作，担任全球区域业务管理负责人的助理一职。之后的两年中，他在公司德国乌珀塔尔的国际战略营销部门工作。

康洛克先生于 1989 年获得德里大学土木工程学士学位，并于 1994 年获得亚洲管理学院企业授予的管理硕士学位。

AMGEN®

Pioneering science delivers vital medicines™

Amgen

美国安进公司

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be the world's largest independent biotechnology company, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential. The company has opened a China headquarter office in Shanghai and a Regulatory office in Beijing.

In 2013 Amgen established a joint venture with Betta Pharmaceuticals Co., Ltd., a leading innovative pharmaceutical company in China. Also in 2013, Amgen announced collaboration with ShanghaiTech University that includes opening a China R&D center, to be housed on the ShanghaiTech campus.

Amgen is growing its business in China around a multi-pronged strategy which includes exploring local manufacturing opportunities as well as partnerships and acquisitions that can help accelerate Amgen's commercial presence in China.

美国安进公司致力于发掘生物科技的潜力，研发、生产创新药物以造福广大重病患者。这一使命始于对人类基因组深入的遗传学分析和复杂致病机理的全面研究。

安进专注于重大疾病的治疗，利用生物药品生产方面的专业知识来改善提高人们的健康状况和生活水平。自 1980 年成立以来，安进公司一直是生物科技领域的先驱，主要关注的重大疾病领域包括：肿瘤、心血管疾病、代谢和免疫紊乱等。目前安进公司已经成长为世界上最大的独立生物科技企业，其创新药物造福了全世界数百万的患者。此外，公司还拥有一批极具潜力的在研药物。

安进公司已经在上海设立了中国总部，并在北京设立了办公室，负责临床注册和合规等业务。安进公司正在国内积极开展临床研究，计划不断引进创新药物，用以治疗肿瘤、心血管等重大疾病。

2013 年，安进公司与国内创新药的领先企业浙江贝达药业有限公司成立了合资公司。同年，安进公司宣布与上海科技大学合作，合作内容包括在上海科技大学校园内设立安进中国研发中心。

安进公司正在国内积极拓展业务，确立了齐头并进的中国战略，包括寻求建立本地生产能力，与国内企业的合作以及在华并购等机遇，从而加快安进公司在国内的业务发展。

James Li
Vice President & General Manager, Greater China,
Amgen

李怡平
副总裁 , 大中华区总经理
美国 Amgen 公司

AMGEN®
Pioneering science delivers
vital medicines™

Dr. James Li is the Vice President and General Manager, Amgen China where he is leading company's efforts in expanding business into Chinese market and help Chinese patients to access Amgen's vital medicines.

Prior to joining Amgen, James was a Partner at Kleiner Perkins Caufield & Byers

life science practice, first in the US Pandemic Fund and later, in its China Fund. He successfully invested in a number of early stage and growth stage companies, and led a portfolio company went to public in 2010.

From 1991 to 2006, James spent over 15 years with Merck Co. & Inc. where he held leadership positions with increasing responsibilities in clinical research,regulatory affairs, new product development and franchise management, both in the US and Asia Pacific/China. During his tenure, he was instrumental in obtaining regulatory approvals of Merck vaccines across Asia Pacific Region when the Vaccine Division started operations in the region, successfully built the foundations of Merck's medical operations in China and drove the success of Merck's largest franchise in Asia.

James received his Medical Degree from Shanghai Medical University, followed by a Master of Science degree in Microbiology from the University of Montana.

李怡平先生是美国 Amgen 公司副总裁 , 大中华区总经理。他目前领导 Amgen 公司在中国的扩展战略并致力于帮助中国患者早日受惠于 Amgen 公司的重要产品。 在加入 Amgen 公司之前 , 李怡平是美国 KPCB 基金生物医药领域的投资合伙人 , 他先后参与了美国流行病基金和中国基金 I 期 , 成功投资了一系列早期和成长期公司并带领了一家公司成功在美国上市。

1991 年至 2006 年期间 , 李怡平在美国默克制药公司的美国总部、亚太区和中国区服务 15 余年 , 在临床研究、药品注册、 新药开发和市场营销等领域担任领导职位。在职期间 , 他成功的帮助了默克疫苗部在亚太各国的疫苗注册和上市 , 奠定了默克中国医学部的基础 , 领导了默克公司在亚洲最大产品销售的高速增长。李怡平毕业于上海医科大学 , 其后又在蒙大拿大学获得微生物学硕士学位。

FOSUNPHARMA
复星医药

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

上海复星医药（集团）股份有限公司

Fosun Pharma is a leading healthcare company in the PRC. Fosun Pharma was established in 1994 with headquarters located in Shanghai, and was listed on the Shanghai Stock Exchange in 1998. In October 2012, though the international financial environment was unfavorable, the Company

successfully completed offering and listing H shares in Hong Kong. As a result, the Company has listings in both the A share market and the H share market. Fosun Pharma has achieved significant results with strengthened corporate governance and investor relationship management. In addition to the SSE 180 Index, CSI 300 Index, SSE Dividend Index and SSE Corporate Governance Index, Fosun Pharma is also included in the SSE Private Enterprise 50 Index, SSE Social Responsibility Index and CCTV Financial 50 Index. According to IMS, Fosun Pharma was one of the top five domestic pharmaceutical companies in the PRC by revenue in the pharmaceutical manufacturing segment in 2011. Fosun Pharma 's business operations strategically cover multiple important segments in the healthcare industry value chain, with business segments including pharmaceutical manufacturing, pharmaceutical distribution and retail, healthcare services and diagnostic products and medical devices.

复星医药是中国领先的医药健康企业，于 1994 年在上海成立及设立总部，于 1998 年在上海证券交易所挂牌上市，并于 2012 年 10 月，成功在香港完成 H 股发行及上市，形成了 A+H 股的资本市场布局。复星医药进一步严格公司治理，加强投资者关系的管理，并取得了显著成效。继入选上证 180、沪深 300 指数、上证红利指数、上证公司治理指数后，复星医药还成功入选上证民营企业 50 指数和上证社会责任指数。以 IMS 2011 年的制药分部收入计算，复星医药是中国五大本土制药公司之一。复星医药的业务战略性覆盖医药健康产业价值链的多个重要环节，业务分部包括制药、药品分销及零售、医疗服务以及医学诊断与医疗器械。

Chen Qiyu

Chairman of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma)

陈启宇

董事长

上海复星医药（集团）股份有限公司

Mr. Chen Qiyu was awarded a Bachelor's degree in genetic engineering from Fudan University and an Executive Master of Business Administration in 2005 from China Europe International Business School.

Mr. Chen joined Fosun Pharma in April 1994 and was appointed as a Director on May 2005. Mr. Chen is the vice president of Fosun International Limited, vice chairman & non-executive director of Sinopharm Group Co. Ltd., director of Zhejiang D.A. Diagnostic Company Limited, vice chairman & director of Tianjin Pharmaceuticals Group Co. Ltd. . Mr. Chen is also a Member of the Chinese People's Political Consultative Conference Shanghai twelfth session of the Committee, vice president of Shanghai Youth Federation.

Mr. Chen is the vice president of China Pharmaceutical Industry Research and Development Association, vice council chairman of the China Medicinal Biotechnology Association, vice president of the China Pharmaceutical Industry Association, chairman of the Shanghai Biopharmaceutical Industry Association and council member of the Shanghai Society of Genetics.

陈启宇先生毕业于复旦大学遗传工程系，获得学士学位；2005 年自中欧国际工商学院毕业，获高级管理人员 MBA。

陈启宇先生于 1994 年 4 月加入复星医药，并于 2005 年 5 月获委任为董事，现为复星国际有限公司副总裁、国药控股股份有限公司副董事长及非执行董事、浙江迪安诊断技术股份有限公司董事、天津药业集团有限公司副董事长。同时，他还是中国人民政治协商会议上海市第十二届委员会委员、上海市青年联合会副会长。

陈启宇先生担任的社会职务有中国医药工业科研开发促进会副会长、中国医药生物技术协会副理事长、中国化学制药工业协会副会长、上海生物医药行业协会会长及上海市遗传学会理事等。

Profile of Jiangsu Hengrui Medicine Co., Ltd.

江苏恒瑞医药股份有限公司

Jiangsu Hengrui Medicine Co., Ltd., established in 1970 and listed in Shanghai Stock Exchange in 2000, holding the idea of "create a healthy life based on science and research" and philosophy of "quality first, integrity management", is the largest research and manufacturing base of antineoplastics and surgical medicine in China as well as the special incubator base for "New Drug Development". Know as the lead of National Anti-tumor Medicine Production Technology Innovation Alliance, one of the most innovative pharmaceutical enterprises, Jiangsu Hengrui Medicine is also the National Key High-tech Enterprise and industrialization base of National Science and Technology Major Project (863 Project), which has a national engineering technology research center of targeted drugs and National Post-doctoral Scientific Research Workstation. Hengrui has established four R&D centers in US, Shanghai, Chengdu and Lianyungang, as well as a clinical medicine department. There are more than 1, 300 High-level professional and technical personnel, among which 55 overseas talent are introduced and five of them belongs to Recruitment Program of Global Experts. Scientific research funds occupy more than 10% of sales every year. In recent years, Hengrui undertakes four projects of National Science and Technology Major Project (863 Project) and 23 projects has been placed to "Major New Drug Development". About 200 patents for invention have been applied, among which 85 are global patent (PCT). The innovative drug Imrecoxib has been approved for marketing; two innovative drugs have been submitted for manufacturing; another eight innovative drugs are in different stages of clinical research. Over the last three years, injection drug and oral preparation has been certified by U.S. FDA and EU, and sold in overseas market. Therefore, Hengrui becomes the first national pharmaceutical enterprise which penetrates into U.S. and European markets with domestic injection products. Jiangsu Hengrui Co., Ltd will continue to devote itself to making Chinese people be available of advanced international standard drugs with reasonable price.

江苏恒瑞医药股份有限公司始建于 1970 年，2000 年在上海证券交易所上市。公司以“科研为本，创造健康生活”为理念，坚持“质量第一，诚信经营”为原则，目前已发展成为国内最大的抗肿瘤药、手术药物的研究和生产基地，国家“重大新药创制”专项孵化器基地、国家抗肿瘤药技术创新产学研联盟牵头单位、国内最具创新能力的制药企业之一，同时也是国家重点高新技术企业、国家高技术研究发展计划（863 计划）成果产业化基地，建有国家靶向药物工程技术研究中心、国家博士后科研工作站。公司在美国、上海、成都和连云港建有四大研究中心和一个临床医学部，拥有各类高层次专业技术人员 1300 余名，并引进了 55 名海外高层次人才，有 5 名国家“千人计划人才”，每年科研经费占销售额的 10% 以上。近年来，公司先后承担了 4 项国家 863 计划重大科技专项项目、23 项国家“重大新药创制”专项，共申请了 200 项发明专利，其中 85 项全球专利（PCT 专利），有 1 个创新药艾瑞昔布已获批上市，2 个创新药已申报生产，另有 8 个创新药处于不同的临床阶段。近三年，公司注射剂和口服制剂先后通过美国 FDA 和欧盟认证，在海外主流市场销售，成为中国首家将国产注射剂打入欧美市场销售的民族制药企业。公司将继续致力于让中国老百姓以合理的价格用上国际先进品质的药品。

Sun Piaoyang
Chairman
Jiangsu Hengrui Medicine Co., Ltd

孙飘扬
董事长
江苏恒瑞医药股份有限公司

Mr. Sun Piaoyang, doctoral candidate, fellow senior engineer, who enjoys the State Council Special Allowance, is the chairman of Jiangsu Hengrui Medicine Co., Ltd, also appointed as vice president of Jiangsu Association for Science and Technology, and vice president of Jiangsu Federation of Industry and Commerce. He was conferred as the second national "Excellent Builder for the Construction of Chinese Characteristic Socialism", member of the eighth and ninth National Pharmacopoeia Committee, delegate of the eleventh, and twelfth session of the National People's Congress (NPC), second-level candidate of Jiangsu "333 Human Resource Project", and he also won the first Innovative Talent Award of Jiangsu Province, the Outstanding Contribution Award of "Eleventh Five-year Plan" National Science and Technology Plan Implementation, Science and Technology Innovation Entrepreneur Award from All China Federation Of Industry And Commerce (ACFIC), elected as outstanding communist party member and excellent entrepreneur of Jiangsu province for many times. He was responsible for and involved in four projects of "863 Project", nine projects of "Major New Drug Development Project", 86 national invention patent applications, 35 global patent applications. Started as a small pharmaceutical company, Jiangsu Hengrui has developed into a R&D and manufacturing base of antineoplastics and surgical medicine, a key Hi-Tech enterprise and one of the most innovative pharmaceutical enterprises in China under his leadership.

博士研究生，研究员级工程师、享受国务院特殊津贴。现任江苏恒瑞医药股份有限公司董事长、江苏省科协副主席、江苏省工商联副主席。第二届全国“优秀中国特色社会主义建设者”，第八、九届国家药典委员会委员，十一、十二届全国人大代表，江苏省劳动模范，江苏省“‘333’工程”第二培养层次人才，获江苏省首届创新创业人才奖、科技部“十一五”国家科技计划执行突出贡献奖、全国工商联科技创新企业家奖，多次被评选为江苏省优秀共产党员、优秀企业家，先后由本人负责和参与了 4 项“863”计划项目以及 9 项国家“重大新药创制专项”的研究，申请国家发明专利 86 项，世界专利 35 项。在其领导下，恒瑞医药由一个小药厂发展成为国内最大的抗肿瘤药物和手术用药的研究和生产基地、国家重点高新技术企业、国内最具创新能力的制药企业之一。

TTY Biopharm Co., Ltd.

台湾东洋药品工业股份有限公司

TTY is a company established in Taiwan since 1960. Since its establishment, the company has encountered several re-structure phases and evolved from a traditional generic pharmaceutical manufacturer to a new drugs development biotech pharmaceutical company. It is in the recent 10 years that TTY developed its strength and capability and focus on specialty biologics and new medical entities for unmet medical needs. The definition for specialty shall mean anything that are patentable and with high barrier innovations. TTY also strives for enhancing the global leverage, and certified to meet EMEA and US FDA inspection standards for producing drugs.

TTY's service and capability across almost the whole industry value chain; starting from proof of concept validation, building formulation technology platform, in-house CRAs, strategic regulatory affairs, & sale and marketing force throughout the island and Mainland China.

TTY specializes in oncology business development in the global market; continues to develop and market Critical Infectious drug portfolios. The company is pulling all the efforts of R&D, Technology and Marketing/Sales together and focus on these two areas. TTY is eager to expand its product portfolio and welcomes partners to co-develop new products for the global market. In the future, TTY will continuous in cultivating the home market in Asian and explore business partnership and opportunity globally.

台湾东洋致力于成为药品开发及国际市场行销生技药厂，一方面不断提升台湾东洋与国际接轨的能力，如国际化文件规格 (CMC、CTD) 能力、国际临床试验执行能力、符合 EMEA、FDA 规格之制造生产能力等。另一方面，持续严选全球新药开发合作伙伴与各地目标市场之最适合作伙伴。台湾东洋除了持续经营台湾地区的核心通路 (医学中心、区域医院、具发展潜力之地区医院) 外，将以发展高障碍、已被证实疗效之创新剂型药物及生物制剂进军国际市场。目前已成功将自行研发的药品推进欧盟、亚太地区、中东地区、非洲及南美洲多个国家，并已成为该区域里强于药品业务行销公司之最佳合作伙伴；未来，将持续深耕亚洲目标市场 (Home market)，建立在地实力，成为国际生技创新公司在华人市场的最佳药品开发与市场行销合作伙伴，期望能以低度资本投入开发创新型，具高度竞争障碍及高度药品经济价值之药品、生物制剂、全新成份新药，创造最佳获益，与国际合作伙伴一同长期稳健发展、共好。

Lin Rongjin

Chairman & General Manager
TTY Biopharm Co., Ltd

林荣锦

董事长兼总经理
台湾东洋药品工业股份有限公司

Mr. Lin Rongjin currently holds the position at TTY Biopharm Co., Ltd. in Taiwan as Chairman & General Manager. Mr. Lin also held several chief executive management roles in various pharmaceutical companies for over the past 30 years.

Mr. Lin is specializing in company re-structuring and building pharmaceutical business strategy and establishing strategic management. From a traditional generic pharmaceutical company to a new drugs development biotech pharmaceutical company, Mr. Lin has been leading TTY through various difficult restructuring stages and helped TTY to become the first restructured local pharmaceutical company in Taiwan. He drove TTY to be listed as a public company and trade-over-counter under the Biotechnology Industry session of Taiwan stock market.

Mr. Lin helps to build up the strength and capability of international marketing and sales force, and turns over TTY to be a biopharmaceutical, new drug development and research oriented company focusing on new oncology drugs, biologics, & innovative drugs. TTY currently sells its products through agents over 30 countries around the world. Mr. Lin has successfully restructured and reorganized 3 enterprises in Taiwan and China.

林荣锦先生现职为台湾东洋药品工业股份有限公司董事长兼总经理，晟德大药厂股份有限公司董事长，智擎生技制药股份有限公司董事长，永昕生物医药股份有限公司董事长，玉晟创业投资股份有限公司董事长。

林荣锦先生领导台湾东洋药品工业股份有限公司，成为本土药厂中，第一家经过重整，在台湾股市上柜的公司。林董事长建立起台湾东洋于生技制药市场之行销布局与销售整合能力，更于近年成功地将以往定位为学名药厂的台湾东洋转型为新药研发公司。转型后的台湾东洋，将资源集中于特殊剂型药物（可专利或高障碍特性）、生物制剂与新药之开发与制造，并将目标聚焦于国际行销及国际创新公司之合作案。

林荣锦先生曾主导三家企业之重整与组织再造，倚仗他的独到眼光，让这三家企业转亏为盈。

Simcere Pharmaceutical Group

先声药业

Founded in 1995, Simcere swiftly evolved from being a pure distributor of pharmaceutical products to become a leading manufacturer and supplier of innovative drugs in China. In the recent years, Simcere's multiple approaches including the strategy focusing on first-to-market product, the combination of in-house R&D with mergers and acquisitions to introduce new products and the joint development of new drugs with international big pharmaceutical enterprises have brought the company closer towards excellence.

Simcere currently manufacture and sell over 45 principal pharmaceutical products, covering a range of medical conditions such as tumors and cardiocerebral vascular diseases and infections. To fuel the company's sustained growth and demonstrate our commitment to research and development, we established the Simcere Pharmaceutical Research Institute. In recent years, Simcere has averaged a 6-11% reinvestment of the company's annual revenue in R&D activities. From 2010 to 2013, Simcere submitted applications to the SFDA to conduct clinical trials of eight innovative drugs. This is exciting progress and a tremendous step forwards.

In the past 6 years, Simcere have filed a total of 200 patent applications, with 18 of them as PCT applications. Simcere's innovative products has received national recognitions such as Second Prize of National Science and Technology Progress, gold medal of the "10th Outstanding Chinese Patent Invention Award", Second Prize of the "2008 National Tech & Invention Award". In 2013 and 2013, Simcere has consecutively been entitled as the "most innovative company of medical and pharmaceutical industry" by China SFDA Southern Medical Economy Institute.

先声药业成立于 1995 年，19 年创业过程，也是凝聚更多资源、持续创新的历程。先声先后作出了放弃普药经销、开始首仿药开发、并购创新药、成立研究院自主研发、引进海外人才、与国际巨头联合研发等一系列循序渐进的战略选择，这些探索正初见成效。

目前，先声药业拥有 45 种以上药品的强大产品组合，重点覆盖抗肿瘤、心脑血管、感染等疾病治疗领域，其中多个产品占据市场领先地位。先声药物研究院于 2004 年成立，有多个技术平台，可进行化学药品和生物药品的研究。最近 5 年来，先声的年研发投入占销售收入的比例均在 6%–11%。2010~2013 年间，先声药业共有 8 个一类创新药进入临床研究阶段，这是中国 4000 多家制药公司中少数几家取得如此进展的企业。过去的 6 年，先声药业研究院共提交了 200 多项国内和 PCT 专利申请，二个创新药先后获国家科技进步二等奖和国家技术发明二等奖、第十届中国专利金奖，先声药业因此被中国医药工业信息中心、南方医药经济研究所评为 2012、2013 年中国医药行业最具创新力公司。

Ren Jinsheng

Chairman of the board of directors and Chief Executive Officer
Simcere Pharmaceutical Group

任晋生

董事长兼首席执行官
先声药业集团

Mr. Ren JInsheng is Simcere's founder, chairman of the board of directors and Chief Executive Officer. He is well-known as a domestic entrepreneur consistently pursuing his dreams, dreams of creating true innovation in China. In the recently years, he has consecutively been recognized as "Pharmaceutical Entrepreneur of the Year", one of "the 60 prestigious Characters of the Pharmaceutical Industry in 60 Years", "Top Ten Outstanding entrepreneur in the health industry", to name a few. He is also a deputy director of China Pharmaceutical Industry Research and Development Association and a vise chairman of Jiangsu Provincial Association of Science and technology.

As Simcere continuously reinforce its commitment to innovation, and partnering with famous oversea enterprises and institutes including OSI, EPITOMICS\BMS and Merck, Jinsheng Ren has gained deeper insights in the industry and started to build a brand-new program, the Bioscikin Enterprise Program. The BioSciKin vision is to develop an integrated life science campus that houses and incubates start-ups in the life science and healthcare technologies space, leveraging Simcere's expertise, resources and support in areas including analytical research, clinical development, registration, manufacturing and commercialization. The BioSciKin initiative also includes a seed fund component which will invest capitals in addition to other resources

任晋生，先声药业创始人，现任先声药业集团董事长兼首席执行官。中国本土医药企业中执着于新药创新的追梦人，先后当选医药行业年度风云人物、中国医药60年60人、连续三年蝉联《医药经济报》中国医药行业“十大锐力人物榜”。担任社会职务：中国医药工业科研促进会副会长、江苏省科学技术协会副主席。

近年来，先声药业每年将销售额的6%-11%投入新药研发，同时与OSI、EPITOMICS、百时美施贵宝、默克等跨国药企和国际研发机构展开多种形式的新药研发合作。

根据过去十年投入创新药的经验和教训，在任晋生的主导和推动下，先声药业目前正在启动创新药物百家汇项目，变以前封闭式创新为开放式创新，建立通用研发平台，凝聚100个创新团队（以海外为主），组建风险投资基金，投资和培植100家创业公司。

AstraZeneca
阿 斯 利 康

AstraZeneca China

阿斯利康中国

AstraZeneca is a global, innovation-driven pharmaceutical company specialising in the discovery, development, manufacturing and marketing of life-changing medicines. We work in over 100 countries with more than 50,000 employees worldwide to meet unmet patient needs.

AstraZeneca entered China in 1993. During our 20 years in China, we have been committed to meeting the healthcare needs of Chinese patients by bringing together talented people who make a meaningful difference in patient lives through innovative science, transformative medicines and executional excellence. We are headquartered in Shanghai and have more than 8,000 employees throughout China. In China, AstraZeneca focuses on the therapeutic areas that local patients need most: Cardiovascular, Diabetes/Metabolism, Oncology/Neuroscience and Gastrointestinal/Respiratory/Anaesthesia. As China is one of the key markets and growth drivers for AstraZeneca, we are committed to long-term planning and investment. We accomplish this by working to achieve scientific leadership, accelerate growth and be a great place to work.

AstraZeneca China recognizes that our people are at the core of everything we do. In 2014, AstraZeneca China was named a "China Top Employer" by the Top Employers Institute for the fourth consecutive year.

Since entering China, AstraZeneca has taken an active role in fulfilling our social responsibilities and contributing to China's goal of being a harmonious society. We do this by working closely with our stakeholders and making contributions to sustainable development in communities around us in China. In 2013, AstraZeneca China was honoured with the "21st Century Best Business Model" and "Best Corporate Citizen" awards organized by 21st Century Business Review and 21st Century Business Herald.

阿斯利康是一家以创新为驱动的全球性生物制药企业，专注于研发、生产和销售处方类药品，为医疗行业带去意义深远的变化。通过创新的研发和全球卓越的研发和商业运作能力，为患者提供优质的药物是公司的业务战略。我们拥有 50,000 多名员工，业务遍布全球 100 多个国家。

1993 年，阿斯利康进入中国市场。20 年来，我们不断吸引人才，通过科研创新以及卓越的执行力，真正改变患者的生活，以不断满足中国的医疗需求。阿斯利康中国总部位于上海，在全国拥有 8,000 多名员工。在中国，阿斯利康的业务重点主要集中在中国患者最需要的治疗领域：心血管、糖尿病及代谢、肿瘤及中枢神经领域、消化 / 呼吸 / 麻醉。中国是阿斯利康最重要的市场之一，也是我们的增长引擎，我们致力于对中国市场的长期投入。为实现这个目标，我们致力于取得研发上的领先地位、加速业务增长、成为理想的工作场所。

阿斯利康中国一直将员工视作一切的核心。2014 年，阿斯利康中国连续第四年荣获由杰出雇主协会颁发的“中国杰出雇主”称号。

自进入中国以来，阿斯利康中国积极履行社会责任，通过与利益相关者的密切合作，以及支持身边社区的可持续发展，为中国实现构建和谐社会的目标贡献力量。2013 年，《21 世纪商业评论》和《21 世纪经济报道》评选阿斯利康为“最佳企业公民”并授予“21 世纪最佳商业模式创新奖”。

David Snow

President of AstraZeneca China and Hong Kong

大卫 · 思诺

中国和香港地区总裁

阿斯利康

AstraZeneca 阿 斯 利 康

Mr. David Snow leads the AstraZeneca China and Hong Kong organizations. In 2013, AZ China grew by 19% to more than $1.8B in China sales and now employs more than 7,000 employees across 4 business units. AZ has had a presence in China for more than 50 years, entering the modern era in 2001 with the opening of the Wuxi manufacturing site. Since then, AZ has continued to invest heavily in China, and especially focused on research and development across diseases affecting Asian patients.

David has more than 25 years of commercial business experience across many leadership roles and therapeutic areas. Previously, he served as Vice President of the United States Cornerstone Business Unit in Wilmington, Delaware. Under his leadership, this business achieved $4 Billion in 2011 sales across a diverse portfolio of over 20 brands. David has been with AZ since 2001 and prior to AZ, worked in other US and German Pharmaceutical companies.

David earned his BA in Marketing from Auburn University and his MBA from the Stern School of Business (NYU).

大卫 · 思诺先生负责领导阿斯利康中国和香港公司。2013 年，阿斯利康中国销售收入增长达 19%，销售额超过 18 亿美元。阿斯利康中国目前有四大业务部门，拥有员工人数超过 7,000 人。阿斯利康已在中国业务运营长达 50 年。2001 年，无锡生产基地投入使用，开启了阿斯利康在中国发展的新纪元。此后，阿斯利康持续大力投资中国市场，并特别针对影响亚洲患者的疾病开展研发。

大卫拥有超过 25 年商务管理经验，曾在多个治疗领域担任过众多领导职位。此前，大卫在位于美国特拉华州威尔明顿地区的阿斯利康美国总部工作，曾担任阿斯利康美国地区成熟品牌业务部副总裁。在他的带领下，该业务部的 20 多个成熟品牌在 2011 年取得了 40 亿美金的销售业绩，大卫于 2001 年加入阿斯利康，此前，他曾在美国和德国的其它制药企业任职。

大卫拥有奥本大学市场营销学士学位及（纽约大学）斯特恩商学院工商管理硕士学位。

Betta pharmaceuticals Co., ltd.

贝达药业股份有限公司

Betta pharmaceuticals Co., ltd., founded by PhD returnees in 2003, is recognized as a full-capacity pharmaceutical company in China and a modern high-tech enterprise. Our portfolio of products and pipeline of investigational drugs include treatments for cancer, diabetes, cardiovascular and cerebrovascular diseases.

R&D is at the heart of fulfilling Bettapharma's mission to translate advanced science and technologies into the therapies that benefit patients most. Bettapharma's executive and R&D leadership team includes seven overseas returnees with Ph.D or MD degree. Five of them have been elected as national distinguished experts by Recruitment Program of Global Experts. The team has received a number of awards such as Chinese Overseas Contribution Award.

Yuhang economic and technological development zone houses Bettapharma's headquarter and manufacture site. The 40 mu facility is with 11 GMP certifications of API, and Drug Products of tablets and ointments. To meet the demand of fast market growth and production, a new 147 mu manufacture site is under construction.

Bettapharma's first NDA, target therapy oncology drug—Icotinib, has been approved by CFDA and marketed under the name of Conmana© in 2011. Icotinib has been cited by Citelines' Pharm R&D Annual Review 2012, the first NCE developed in China ever been cited. Bettapharma's Icotinib has received patent gold metal awarded by WIPO and SIPO, First Prize of Zhejiang Science and Technology awarded by Zhejiang Province. Phase III clinical trial results of Icotinib has been published at Lance Oncology on August 2013 and honored by editor's comments as "Icotinib: kick-starting the Chinese anticancer drug industry".

Over the past 10 years, we have filed more than 80 PCT applications and been granted 7 patents. Icotinib API and drug product standard have been awarded as national standard. Bettapharma's R&D has received two of MOST Innovation Fund, one of "863"High-tech Plan, one Torch plan fund and six of Significant New Drugs Creation fund. In addition, Bettapharma has been listed on 2014 China's Most Potential Enterprises by Forbes and has become one of the best non-listed enterprises in China. Forbes also made Bettapharma and the founders its cover story.

Bettapharma has partnered with Eli Lily Pharmaceutical by Strategic Investment and received the Zhejiang Best Investment Value Award in 2010. To co-promote Amgen's Vectibix® (panitumumab) at the Chinese market, Bettapharma signed a strategic agreement with Amgen to set up a joint venture, Amgen-Betta Pharmaceuticals Co.,Ltd., which is located in Zhejiang Hi-tech Park.

In our pursuit to improve the lives of people, Bettapharma is committed to realizing the promise of "Better Medicine, Better life', firmly focused on our Mission to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

贝达药业股份有限公司成立于 2003 年 1 月，是一家由海归博士团队创办的以自主知识产权创新药物研究和开发为核心，集研发、生产、营销于一体的国家级高新制药企业，主要研究领域为恶性肿瘤、糖尿病、心脑血管等严重影响人们健康的疾病。

公司在杭州建有生产基地 40 亩，拥有 GMP 认证的片剂和膏剂生产车间和原料药、肿瘤口服制剂等 11 个国药准字号药品生产批文。为满足日益增长的市场和生产需求，占地 147 亩的新生产基地也在积极规划筹建中。公司在北京设有研发中心，现有 100 余名新药研发人员，包括 7 位留学归国博士，其中 5 位已入选中组部“千人计划”。公司还拥有一支 200 余人的市场营销团队，在全国设有 8 个办事处。

2011 年，公司自主研发的国家一类新药盐酸埃克替尼（凯美纳）正式获批上市，被列入美国权威机构发布的全球新药研发年度报告，并获世界知识产权组织和国家知识产权局联合授予的“专利金奖”。2013 年 8 月，世界顶级杂志《柳叶刀 肿瘤篇》首次全文刊发凯美纳Ⅲ期临床研究成果，并评价“埃克替尼开创了中国抗癌药研发的新纪元”。

公司成立 11 年来，获国内、国外专利授权 7 项，获科技部创新基金 2 项、“863”高科技计划 1 项、国家重大新药创制专项立项 6 项等多项支持。另外，公司荣登福布斯 2014 年中国潜力企业榜，成为中国非上市潜力企业的佼佼者，该杂志也用封面故事对公司和创始人进行了报道。

2010 年公司引进了美国礼来制药战略投资，并被评为“浙商最具投资价值企业”。2013 年，公司与全球生物制药巨头 – 美国安进公司正式签署战略合作协议，成立贝达安进制药有限公司，共同推进安进公司抗癌药物 Vectibix® 在中国的市场化，令中国患者受益。

Ding Lieming

Chairman & CEO,
Betta Pharmaceuticals, Co,.Ltd.

丁列明

董事长兼首席执行官
贝达药业股份有限公司

Dr. Ding Lieming, Chairman & CEO, Betta Pharmaceuticals, Co,.Ltd., NPC delegate.

Graduated from the University of Arkansas College of Medicine and used to be a board certified physician, Dr. Ding came back to China in 2002 and founded Zhejiang Beta Pharma in Hang-Zhou in January 2003 focusing on the development and commercialization of innovative pharmaceutical products in China that include Icotinib, the first targeted cancer therapy that was developed by a Chinese company. Icotinib, which was launched in Aug.2011, creates a miracle in China's pharmaceutical history with a total sale of 800 million (by 2013),for which Bettapharma was listed as China's Most Potential Companies in 2014 by Forbes, with Dr. Ding as the cover story. Dr. Ding is well recognized as one of the key leaders on pharmaceutical innovation in China and received many national awards including the Outstanding Accomplishment Award from MOST in 2011. Dr. Ding is a distinguished advisor to the All-China Federation of Returned Overseas, and is the chairman of the pharmaceutical innovation committee for the Chinese Program of Global Experts (also known as the "1000 Plan").

丁列明，美国阿肯色大学医学博士，贝达药业股份有限公司董事长兼首席执行官，第十二届全国人大代表，中国侨联第九届委员会委员，中国农工党中央生物技术与药学工作委员会副主任，中国药学会常务理事，国家“重大新药创制”科技重大专项总体组专家，中国侨联特聘专家，享受国务院特殊津贴。

2002 年底，丁列明回国创业，在杭州创建贝达药业，主要从事创新药物的研究和开发。其主导产品国家一类新药盐酸埃克替尼（凯美纳），经长达十年的研究开发，已于 2011 年 8 月成功上市。该新药的成功开发填补国内小分子靶向抗癌药的空白，被卫生部陈竺部长誉为民生领域的“两弹一星”。在丁列明的带领下，贝达药业荣登福布斯“2014 年中国潜力企业榜”第 5 名，他也登上了福布斯杂志封面。目前凯美纳总销售额已突破 8 亿，创造了中国新药史上的奇迹。

丁列明于 2009 年入选国家“千人计划”，并任“千人计划”专家联谊会新药创制和产业化工作组组长；2010 年获中国侨联的“创新人才”奖和团队贡献奖（2012 年）；2011 年获国家科技部“十一五”国家科技计划执行突出贡献奖，并被评选为“2011 年中国健康行业创新领袖”；2013 年荣获第二届世界浙商大会创业创新奖、浙江省科学技术一等奖和浙江省十佳优秀科技工作者。

RDPAC

中国外商投资企业协会药品研制和开发行业委员会 (RDPAC)

Under the China Association of Enterprises with Foreign Investment (CAEFI), the R&D-based Pharmaceutical Association Committee (RDPAC) is a non-profit organization made up of 40 member companies with pharmaceutical R&D capability.

Till now, the member companies have 49 plants and 30 R&D centers. In the last five years, RDPAC members have introduced at least 67 innovative drugs for the benefit of Chinese patients, representing over 80% of all innovative drugs introduced to China during this period.

The Chinese government, local companies and RDPAC members share a similar vision to see China become a leading global innovation partner. RDPAC welcomes the opportunity to continue to partner with the government to reach our joint aspiration for the benefit of Chinese patients.

Our Vision

HEALTHIER CHINA THROUGH INNOVATION

To be a valued partner in delivering the "Healthy China 2020" goal to improve the health and quality of life of people in China:

- Providing our high-quality/ innovative healthcare products and services in a socially responsible
- and commercially viable manner;
- Committed to securing patients timely access to innovative & high quality drugs;
- Achieving highest standard of integrity for ethical research and business practice;
- Contributing to the growth of the biopharmaceutical sector in China;
- Supporting the development of a sustainable healthcare system in China.

中国外商投资企业协会药品研制和开发行业委员会（RDPAC）是一个由 40 家具备研究开发能力的跨国制药企业组成的非赢利性组织，隶属于“中国外商投资企业协会”。

目前，RDPAC 会员公司已在中国设立了 49 家工厂，30 个研发中心，在过去五年中，RDPAC 成员已累计向中国市场引进了至少 67 种创新药物，占到了同期中国市场所有上市创新药物的 80%。

RDPAC 成员与中国政府、本土医药企业抱有一个共同的愿望，即希望中国成为医药创新大国。RDPAC 期待有机会和中国政府共同努力、协同发展，实现这一愿望，使创新药物惠及更多中国和全球患者。

愿景：创新引领健康中国

致力于成为中国实现“健康中国 2020”目标以及不断提高居民和患者生活质量的重要合作伙伴：

- 兼顾社会责任与行业发展，为中国提供高质量的、创新的医疗健康产品和服务；
- 为确保患者及时获得质优及创新药品而努力；
- 在研究和商业运营中保持诚信，遵循最高标准道德规范；
- 对中国生物制药产业的发展做出积极的贡献；
- 支持中国建立可持续发展的医疗卫生体系。

Joseph Cho

Managing Director, RDPAC

卓永清

执行总裁

中国外商投资企业协会药品研制和开发行业委员会 (RDPAC)

Mr. Joseph Cho was appointed as Managing Director of China Association of Enterprises with Foreign Investment R&D-based Pharmaceutical Association Committee (RDPAC)on April 1, 2011. Joseph is a very knowledgeable and experienced pharmaceutical industry leader, with 35years' experience in pharmaceutical industry in China, Hong Kong and Taiwan.

Since 1999, Joseph has been very active in supporting RDPAC as the Executive Committee member. From 2008 to 2011, he has been acting as Vice Chairman for RDPAC and plays a great role in RDPAC. Having spent more than a decade running a pharmaceutical operating company in China, Joseph fully understands the opportunities and threats facing the industry.

Before joining RDPAC as Managing Director, Joseph was Country President and CEO of Astellas Pharma China. Joseph started off his career as a medical representative in Fujisawa Taiwan in 1977, and then took on increasingly many important jobs in Fujisawa (now known as Astellas after merging with Yamanouchi in 2005) in the past 35 years.

Joseph graduated from National Taiwan University, and he is member of Rotary Club, which dedicates to combat hunger, improve health and sanitation, provide education and job training, and promote peace.

卓永清先生自 2011 年 4 月 1 日起担任中国外商投资企业协会药品研制和开发行业委员会（RDPAC）执行总裁。他知识渊博、经验丰富，在中国台湾、香港和大陆等地拥有 34 年医药行业从业经验，是研发制药行业杰出的领导者之一。

1999 年，卓永清先生成为 RDPAC 执行委员会成员，自 2008 年起担任 RDPAC 副主席。凭借在大陆 10 余年的制药企业运营管理经验，卓先生对研发制药行业所面临的挑战和机遇都有深刻的洞见。

在担任 RDPAC 执行总裁前，卓永清先生在安斯泰来制药（中国）有限公司任董事长兼总经理，他于 1977 年加入台湾藤泽制药公司（现安斯泰来制药），并不断获得晋升。卓永清先生于 2011 年 3 月 31 日辞去安斯泰来制药（中国）有限公司总经理职务，继续公司董事长职务至 2013 年 3 月 31 日。

卓永清先生毕业于台湾大学，也是扶轮社成员 (Rotary Club) 。该社致力于消除饥饿、提升医疗与教育水平，社员均志愿服务社会。

Johnson & Johnson

强生公司

Caring for the world, one person at a time... inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Employees of the Johnson & Johnson Family of Companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

Johnson & Johnson is the world's most comprehensive and broadly based manufacturer of health care products, as well as a provider of related services, for the consumer, pharmaceutical, and medical devices and diagnostics markets. The more than 250 Johnson & Johnson operating companies employ approximately 128,000 men and women in 60 countries, and sell products throughout the world. The company was founded in 1886 in New Brunswick, New Jersey, in the United States.

Johnson & Johnson established its first joint venture in China in 1985. Today, the Company, through its subsidiaries operating in China, employs about 10,000 people.

In 2012, worldwide sales were $67.2 billion, while our total investment in research and development was over $7.6 billion.

“关爱全世界，一次为一人…”，正是这种精神鼓舞着每一个强生人并将他们团结在一起。我们热爱研究和科学，通过推陈出新为人们带来创新的产品和服务，让他们更健康、更幸福。每天，强生公司遍布全球的同仁与医疗合作伙伴携手，致力于关爱全世界十几亿人生命的事业。

强生公司是世界上最具综合性、业务分布范围最广的健康护理产品制造商和服务商，为消费品、制药以及医疗器材和诊断产品的市场提供全面的产品和服务。强生公司在全球 60 个国家拥有 250 多家子公司，雇员约 128,000 名，在世界各地均有其产品销售。强生公司于 1886 年创建于美国新泽西州的新布仑兹维克。

强生公司在中国的第一家合资企业于 1985 年成立。如今，强生公司在华子公司的员工总数共有约 10,000 人。

2012 年，强生公司的全球销售额达 672 亿美元。公司在研发方面的总投入超过了 76 亿美元。

Will Song

General Manager of Global Surgery Group
Johnson & Johnson Medical China

宋为群

大外科总经理
强生（中国）医疗器材有限公司

Mr. Will Song is the General Manager of Global Surgery Group at Johnson & Johnson Medical China, the chairman of the board, and also VP of Ethicon Biosurgery APAC. Will sits on the APAC Regional Leadership Team of medical device business and Global Management Board of Ethicon Biosurgery.

Will joined Johnson & Johnson as the only Global Management Associate in JNJ's 2003 hires from business schools. In 2005, he took over product management role for Cordis Endovascular, Australia and New Zealand. From Oct 2006, he came back to China to be the Franchise Head of Ethicon China, and then lead Ethicon Endo Surgery and Advanced Sterilization Products. From the beginning of 2012, Will took over the surgery group's business in China, and responsible for government affairs, corporate communications, strategic planning and other functional departments.

Will holds a Bachelor of Science degree from Peking University, a PHD in Molecular Biology and Biochemistry from the University of Massachusetts Medical School, and an MBA from the Wharton School, University of Pennsylvania.

宋为群先生现任强生（中国）医疗器材有限公司大外科总经理、董事会主席、爱惜康生物外科亚太地区副总裁。宋为群先生同时也是医疗器材业务亚太地区领导团队、以及爱惜康生物外科全球管理董事会的成员之一。

宋为群先生于 2003 年作为强生唯一的全球管理培训生加入美国强生公司。他于 2005 年就任澳大利亚及新西兰地区的心血管产品市场部工作。2006 年 10 月宋为群先生回国，先后出任爱惜康中国事业部负责人、爱惜康内镜外科及高级灭菌产品部门负责人。从 2012 年初开始，宋为群先生全面接管强生医疗大外科集团的在华业务，并且负责企业政府事务，企业传讯，战略规划等职能部门的工作。

宋为群先生毕业于北京大学细胞生物学与遗传学系，并获得麻州大学医学院分子生物学和生物化学博士学位，宾夕法尼亚大学沃顿商学院工商管理硕士学位（MBA）。

Brife Introduction of Guangxi Wuzhou Zhongheng Group Co., Ltd.

广西梧州中恒集团股份有限公司

Guangxi Wuzhou Zhongheng Group Co., Ltd. (Zhongheng Group) held by the private capital, is a multi-industrial and modern listed company who owns several subsidiaries. Zhongheng Group became the State-level high-tech enterprise.

The strategic structure of Zhongheng Group is TCM industry as the core and jointly development of other businesses including supplement food, hotel, property management and self-capital investment. Zhongheng Group owns the nationwide sole pharmaceutical brand—Zhonghua as well as other famous brands like Chenzhong and Zhongheng. The high-tech products Xueshuantong for Injection, Zhonghua Dieda Pill and Fuyanjing Capsule are awarded the National Invention Patents. The supplement food brand Double Coins is also awarded the China's Time-honored Brand and Double Coins Guiling Gao has make great success.

Zhongheng Group has built up the Asian's largest TCM industrial base covering an area of more than 1 million square meters. In recent years, under the lead of Chairman Xu shuqing and with this TCM base as new development platform, Zhongheng Group develops rapidly and makes great profits in successive years. Now, Zhongheng Group is striving to create newly leap and takeoff.

In the future, Zhengheng Group will seize the historical opportunity brought by Western Development, construction of the Pan-Beibu Gulf Economic Zone and open of the China-ASEAN Free Trade Area, focus on the pharmaceutical industry and dedicate to be the leader of China's pharmaceutical manufacturing industry so as to enter into the market all over the country and world.

广西梧州中恒集团股份有限公司（简称中恒集团）是一家跨行业、现代化、集团化经营的民营控股上市公司，国家级高新技术企业。

中恒集团构筑了以中药制造业为核心主导产业，保健食品为新增长产业，辅以酒店、物业及自有资金投资等业务的战略格局。拥有了全国唯一的医药品牌——中华牌，以及晨钟牌和中恒牌等知名商标品牌，注射用血栓通、中华跌打丸、妇炎净胶囊等高新技术产品获得国家发明专利。在保健食品领域拥有了获得中华老字号的双钱牌，成功打造了双钱牌龟苓膏。

在未来发展上，中恒集团将牢牢抓住西部大开发以及广西北部湾经济开发区建设和东盟自由贸易区开放带来的历史性机遇，集中更大的精力，专注于制药健康产业的创新发展，致力于打造中药制造的领军品牌，成为全国制药行业的领军企业，努力实现走向全国，走向世界。

Xu Shuqing

Chairwoman of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma)

许淑清

董事长

广西梧州中恒集团股份有限公司

Ms. Xu Shuqing is the National People's Congress. She is also the Chairwoman of the board and president of Guangxi Wuzhou Zhongheng Group Co., Ltd., Standing Committee of the National Federation., the vice Chairwoman of Guangxi Federation of Industry, president of the Chamber of Commerce of Guangxi Medical.

Benefit to outstanding achievement and the high responsibly of society, Chairwoman Xu Shuqing make lots of compliment: Model workers; Model women ; outstanding builders of Socialism with Chinese characteristics; top 10 model of contribution; model of helping disable ,top 10 philanthropist of national.

许淑清 , 全国人大代表。现任广西梧州中恒集团股份有限公司董事长兼总裁，并兼任全国工商联常委、广西工商联副主席、广西医药商会会长等职。

辉煌业绩和高度社会责任感使许淑清赢得了社会各界的高度称赞和肯定。先后获得了“全国劳动模范”、“全国三八红旗手标兵”、“全国优秀中国特色社会主义事业建设者”、全国十大“巾帼建功”标兵、“全国扶残助残先进个人”、“中国十大慈善家”等荣誉称号。

赛诺菲

Sanofi in China

赛诺菲在中国

Sanofi has a strong commitment to China. In early 1980s, Sanofi became one of the first foreign pharmaceutical companies to open offices in China. Today, Sanofi has 8,500 employees in China, and is one of fastest growing healthcare companies in the country. Sanofi's China headquarters are in Shanghai, supported by 11 regional offices in Beijing, Tianjin, Shenyang, Shanghai, Hangzhou, Nanjing, Wuhan, Chengdu, Guangzhou, Jinan and Urumqi.

Sanofi currently has seven manufacturing facilities in Beijing (pharmaceutical), Hangzhou (one pharmaceutical, one consumer healthcare), Nanchang (animal health), Shenzhen (vaccine), Tangshan (consumer healthcare) and Nanjing (animal health).

Sanofi is engaged in integrated R&D in China from drug target identification to late stage clinical studies. Its China R&D Center and Asia Pacific R&D Center are based in Shanghai, supported by branches in Beijing and Chengdu. Since 2008, Sanofi has established thirty strategic collaborations on the discovery front with top scientific institutions in China in cutting-edge research in cancer, stem cell, diabetes and age-related diseases.

赛诺菲一直以来秉承对中国的承诺。30 年前，赛诺菲在中国开设办事处，跻身首批进入中国的跨国制药企业，业务覆盖处方药、疫苗、健康药业、罕见病（健赞）和动物保健（梅里亚）。赛诺菲目前在中国拥有 8500 名员工，是国内增长最快的医药健康企业之一。赛诺菲在中国的总部位于上海，并在北京、天津、沈阳、济南、上海、杭州、南京、武汉、成都、广州和乌鲁木齐共设 11 家区域办事处。

赛诺菲目前在中国拥有七家生产基地，包括北京制药工厂、杭州制药工厂、杭州赛诺菲民生健康药业工厂、南昌梅里亚动物保健工厂、深圳赛诺菲巴斯德疫苗工厂、唐山健康药业工厂以及南京动物保健工厂。

在中国，赛诺菲具有从药物靶点发现到后期临床研究的整体研发实力。集团在上海设有中国研发中心和亚太研发中心，并在北京和成都分别设有研发机构。自 2008 年以来，赛诺菲与中国权威科研机构开展了 30 余项战略合作，在癌症、干细胞、糖尿病和老年疾病等前沿研究领域探索创新药物。



Jean-luc Lowinski

Senior Vice President, Sanofi Asia, and President,Sanofi China

龙贤礼

亚洲区高级副总裁，大中华区总裁
赛诺菲

Dr. Jean-Luc Lowinski is Senior Vice President, Sanofi Asia, and President, Sanofi China. In this role, he is responsible for driving Sanofi's strategy in the Asia region which includes Greater China, Southeast Asia (the Philippines, Thailand, Indonesia and Singapore/Malaysia) and Indochina (Vietnam, Laos and Cambodia). He also coordinates Sanofi's diverse businesses in China and represents Sanofi to key external stakeholders.

Prior to joining Sanofi in May 2012, Dr. Lowinski built a successful career in pharmaceuticals, consumer health care and animal health. He began his career in the French Army as a technical volunteer before becoming a veterinarian. He joined Bayer Germany in 1992, where he held various positions, including serving as the head of the company's operations in Singapore, India, Thailand, China and Japan. In 2003, Dr. Lowinski became the head of Bayer Healthcare, China. He then became the head of Bayer Healthcare, Asia Pacific, at the end of 2004. He was appointed President, Bayer Yakuhin, in Japan in 2007. In 2010, he became the global head of Bayer's Animal Health Division.

Dr. Lowinski holds a Ph.D. in veterinary science from the University of Nantes in France and is a graduate of INSEAD. He is a French national and speaks French, English, German, Japanese and Chinese.

龙贤礼博士是赛诺菲亚洲区高级副总裁，兼任中国区总裁。龙贤礼博士负责赛诺菲集团在大中华区、东南亚（菲律宾、泰国、印度尼西亚、新加坡和马来西亚）、印度支那（越南、老挝、柬埔寨）的业务和发展。此外，他还负责协调赛诺菲在中国的各项业务，并代表赛诺菲在高端层面对外沟通。

龙贤礼博士于 2012 年 5 月加入赛诺菲。此前，他在处方药、健康药业和动物健康方面积累了丰富的经验。他最初在法国军队从事技术志愿者，之后他成为了一名兽医。他于 1992 年在德国加入拜耳，之后担任过多个不同职位，其中包括负责拜耳在新加坡、印度、泰国、中国和日本的业务。2003 年，他成为拜耳医药保健中国区负责人，2004 年底，他被任命为拜耳医药保健亚太区负责人。他于 2007 年担任日本拜耳 Yakuhin 的总裁。2010 年，龙贤礼博士成为拜耳动物保健部门全球负责人。

龙贤礼博士拥有法国南特大学 (University of Nantes) 兽医博士学位以及欧洲工商管理学院（INSEAD）工商管理硕士学位。他拥有法国国籍，除法语之外，他还能流利地使用英语、德语、日语和中文。

Cathy Qian

Vice-President
Sanofi China

钱云

副总裁
赛诺菲中国集团

Ms. Cathy Qian joined Sanofi from 2012 and takes the role of Vice-President in Sanofi China. Cathy has more than 26 years healthcare industry experience, including 16 years of public affairs experience in multinational pharmaceutical companies. Before joining Sanofi, Cathy spent 10 years with J&J China leading the Public Affairs & Partnership Development functions. Prior to that, Cathy managed government affairs with Shanghai Roche for 5 years. Cathy was also an active leader and player in several industry associations.

Cathy graduated from International MBA of National School of Development, Peking University. She also has a Bachelor's in Medicine.

钱云女士有着超过 26 年的医药行业工作经验，其中包括 16 年跨国制药公司公共事务工作经验，现任赛诺菲中国集团公共事务副总裁。在加入赛诺菲以前，钱云女士曾在西安杨森制药有限公司工作十年，从政府事务与企业传播部副总监，到公共事务与伙伴关系发展部高级总监。在此之前，钱云女士曾就职于上海罗氏制药有限公司五年，任政府事务和政策研究部经理。钱云女士同时也在多个行业协会任职并发挥其影响力。

钱云女士毕业于北京大学国家发展研究院，拥有国际工商管理硕士学位和医学学士学位。

Helen Gao

Sr. Director, Government Affairs and Market Access,
Greater China
Amgen

高彤

高级总监，大中华区政府事务及市场准入
美国 Amgen 公司

AMGEN®
Pioneering science delivers vital medicines™

Ms. Helen Gao is Sr. Director of Value Access & Policy, Amgen China, responsible for all activities related to government affairs and healthcare policy, access planning and negotiations, pricing recommendations, Helen serves as a member of the China management team as well as the international Value Access & Policy leadership team.

Helen has significant experience in market access, government affairs, healthcare policy, pricing and reimbursement. Since 2011, Helen has worked as Head of External Affairs /Market Access Greater China for Medtronic, based in Shanghai. Prior to that Helen worked for 12 years with Roche in a variety of policy and access roles, and for 3 years with Glaxo Wellcome (now GSK) as Scientific Liaison Supervisor. She has built and managed high-performing teams in each of these roles.

Helen graduated from Capital University of Medical Science and practiced as a physician in Beijing Children's Hospital for three years after her graduation.

高彤在安进公司担任政府事务及市场准入高级总监。职责范围包括所有与政府事务及医疗政策，医保报销策略，定价建议等市场准入相关事宜。高彤为安进中国管理团的其中一员，同时也是全球市场准入及政策领导团队的一员。

高彤在市场准入、政府事务、医疗保健政策及定价和报销方面有很丰富的经验。2011 年，高彤任职于美敦力，担任大中华区对外事务 / 市场准入总监，负责大中华区政府事务、注册法规事务、卫生经济事务及公共关系事务。在此之前，高彤在罗氏有 12 年的工作经验，负责各种政策及市场准入工作，并且在葛兰素威康（现为葛兰素史克）有 3 年的经验，担任科学联络主管。她在历任的职位中都建立并管理了高绩效的团队。

高彤毕业于首都大学，主修医学科学。毕业后 3 年内就职于北京儿童医院，担任医师。

HUANG BIN

Vice President
Government Affairs & Market Access,
AstraZeneca Investment (China) Co., Ltd

黄彬

政府事务及市场准入部副总裁
阿斯利康投资（中国）有限公司

AstraZeneca 阿斯利康

Mr. Huang Bin is the Vice President of Government Affairs & Market Access, AstraZeneca Investment (China) Co., Ltd.

Mr. Huang Bin joined AstraZeneca China as Regulatory Affairs Director in August 2004. From October 2008 to August 2010 he was Senior Director, Global Regulatory Affairs in the AstraZeneca global R&D organization based in Wilmington, Delaware, USA. Upon return, he became Executive Director, Regulatory Affairs in Aug 2010, and took the additional medical and clinical responsibility in late 2010 for the branded generics development.

Prior to joining AstraZeneca, Mr. Huang Bin served in Eli Lilly China for more than 9 years as Senior Regulatory Affairs Manager, Senior Manager on IPR & Industry Affairs in Governmental Affairs Department, and Regulatory Affairs Consultant in Lilly Asia for the Asia regional new drug development. Previously he was a lecturer in the School of Pharmacy, Beijing Medical University from 1992 to 1995.

Mr. Huang Bin holds a Bachelor of Science in Chemistry and Master of Science in Organic Chemistry from Beijing Normal University, and MBA diploma from China-Europe International Business School (CEIBS).

Mr. Huang Bin is a senior member of China Pharmaceutical Association and BayHelix. He is the member of DIA Advisory Committee China (ACC) since 2010 and served as Vice Chairman of ACC since 2012.

黄彬先生任职于阿斯利康投资（中国）有限公司，担任政府事务及市场准入部副总裁，负责管理阿斯利康中国中央和地方市场准入工作和政府事务。

黄彬先生于 2004 年 8 月加入阿斯利康中国，担任药政事务总监。2008 年 10 月至 2010 年 8 月间，他在位于美国威明顿的阿斯利康研发总部任全球药政事务高级总监。2010 年 8 月返回阿斯利康中国后，升任药政事务执行总监。2010 年年末起，黄彬先生同时负责品牌仿制药开发，担任药政事务及品牌仿制药开发执行总监。

加入阿斯利康之前，黄彬先生在礼来公司工作九年多，担任礼来中国药政事务高级经理，政府事务部知识产权和行业事务高级经理，礼来亚洲地区药政事务顾问等职位。1992 年至 1995 年间，他曾在北京医科大学药学院担任讲师。

黄彬先生拥有北京师范大学化学学士学位和有机化学硕士学位。同时，他还拥有中欧国际工商管理学院的工商管理硕士文凭。

黄彬先生是中国药学会高级会员和百华协会（BayHelix）会员。自 2010 年他成为药物信息协会（DIA）中国顾问委员会（ACC）委员，2012 年起担任该委员会副主席。

Joy Lin

Vice President of Bayer Pharma China

林静

公共事务及市场准入部副总裁
拜耳医药保健

Ms. Joy Lin has been appointend Vice President of Bayer Pharma China since October, 2013.

Ms. Li started her career in the pharmaceutical industry in 1990. She has accumulated solid working experience in External Affairs and Market Access arena during the past 15 years. Prior to joining Bayer, Ms. Li has held various positions with increased responsibilities, i.e. Senior Director of Market Access and KA in Xi'an Janssen China, Director of Market Access and CA in Roche China, Director of Market Access in GSK China, Director and Sr. Manager of Market Access in Novartis China.

Ms. Li holds a Master degree of Project Management from Sydney University.

林静女士自 2013 年 10 月起担任拜耳医药保健中国公共事务及市场准入部副总裁。

林静女士于 1990 年投身医药行业，在公共事务与市场准入领域逐步获得提升，积累了广泛而坚实的工作经验，担任过多个重要职位。在加入拜耳之前的 15 年里，林静女士曾担任西安杨森中国市场准入和关键客户高级总监、罗氏中国市场准入和企业事务总监、葛兰素史克中国市场准入总监以及诺华中国市场准入总监。

林静女士毕业于悉尼大学，获项目管理硕士学位。

Stella Ling
Vice President Public Affairs, Bristol-Myers Squibb

凌蕴弢
百时美施贵宝企业事务部副总裁

Haruhiko HIRATE
Corporate Officer,
Senior Vice President, Head of North Asia,
Takeda Pharmaceutical Company Limited

平手晴彦
武田药品工业株式会社
合伙人、高级副总裁、北亚地区主管

CHI-STEVE Chan
CEO, ADIMMUNE CORPORATION

詹启贤
国光生技股份有限公司董事长

Stefan DOBOCZKY
Member,
Managing board director,
Royal DSM

杜博思
荷兰皇家帝斯曼集团，
帝斯曼执行董事会董事

Weiming Jiang
Senior Executive Vice president,
Royal DSM. President, DSM China

蒋惟明
荷兰皇家帝斯曼高级执行副总裁
帝斯曼中国总裁

Jinmei Zheng
ZHENGJIAN (HK) HOSPITAL MANAGE LIMITED

郑金美
正健（香港）医院管理有限公司总裁